Mobile
  • Search
  • Advanced search
  • Multi-criteria search
  • Who are we ?
  • Log in
  • Sign up
  • Français
  • English

Kusajili – Clinical trials directory

Your research

Clear all filters

Filtres
organs
Specialty
Type
Promoter
  • Andrew Armstrong, MD (1)
Country
Source
  • nct (1)
Phase
  • complete (1)

Promoter: Andrew Armstrong, MD
Andrew Armstrong, MD Update Il y a 4 ans

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon which to improve upon. Thus, the primary objective of this study is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).

  • Country None
  • organs None
  • Specialty None
Closed trial
More information

  • 1

Who are we ?

Kusajili was created to respond to a request from physicians to simplify access to patient registries and inclusion. Kusajili is regularly updated according to new French and international trials. [email protected]

Kusajili and MyHomeDoctor

MyHomeDoctor software unique to the world, created with surgeons, for follow-up and analysis of patient follow-up. Kusajili and MyHomeDoctor partners, help clinical research through improved patient follow-up and automatic inclusion.

Sign up

Sign up
Français - English - CGU - Cookies

©2023 Kusajili France - Kusajili International - MedSynApps - MyHomeDoctor.